PharmaEssentia
PharmaEssentia is a Taiwan-headquartered biopharmaceutical company that develops and commercializes BESREMi, an FDA-approved pegylated interferon therapy for polycythemia vera and other myeloproliferative neoplasms, distributed globally across 40+ countries to hematologists and oncology specialists.
- Company typePublic
- Founded2003
- HeadquartersTaipei, Taiwan
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmaEssentia does
PharmaEssentia is a Taiwan-headquartered, publicly listed biopharmaceutical company (TWSE: 6446) founded in 2003 that develops and commercializes pegylated cytokine therapies for rare hematologic diseases. Its lead asset, BESREMi (ropeginterferon alfa-2b-njft), is a next-generation mono-pegylated proline interferon built on a proprietary site-specific PEGylation platform and is the only interferon therapy approved by the FDA for adults with polycythemia vera (PV). BESREMi has secured regulatory approvals in over 40 countries including the U.S., EU, Japan, Canada, and Taiwan, and was recently approved in Taiwan for essential thrombocythemia (ET) — the first new therapy for ET in nearly 30 years — with a U.S. FDA PDUFA target action date of August 30, 2026 for the ET indication.
The company is commercializing BESREMi through a hybrid model combining direct sales operations in the U.S. (PharmaEssentia USA, Burlington, MA) and Canada (FORUS Therapeutics, acquired June 2026 for US$36.5M) with regional channel partners, including AOP Health for Europe/CIS/Middle East (~12,600 patients served) and Pint-Pharma for Latin America. BESREMi is offered as both a prefilled syringe and, following FDA approval in June 2026, a prefilled pen device for self-administration, with a U.S. WAC of approximately US$10,421 per syringe. PharmaEssentia operates GMP biologics manufacturing at Central Taiwan Science Park (capacity to serve ~40,000 patients, scaling to 100,000+), is building a US$46M facility in Puerto Rico for the U.S. market, and is advancing a pipeline that includes PEG-GCSF, an anti-PD-1 antibody, TCR-T cell therapy, bispecific immunocytokines, and novel immune checkpoint antibodies. As of Q3 2025, BESREMi sales reached US$127.8 million (44% YoY growth), with trailing twelve-month revenue growth of 61% and gross margins of 89%, reflecting a single-product-dominated commercial-stage business with substantial pipeline optionality.
PharmaEssentia firmographics
Firmographics- Name
- PharmaEssentia
- Legal name
- PharmaEssentia Corporation
- Website
- https://us.pharmaessentia.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- PharmaEssentia is a Taiwan-headquartered biopharmaceutical company that develops and commercializes BESREMi, an FDA-approved pegylated interferon therapy for polycythemia vera and other myeloproliferative neoplasms, distributed globally across 40+ countries to hematologists and oncology specialists.
- Ownership category
- akta.pro rank
PharmaEssentia industry classification
Industry- Product category
- Hematology Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where PharmaEssentia is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices10 records
Markets served
PharmaEssentia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales (BESREMi): Revenue generated from global sales of BESREMi (ropeginterferon alfa-2b-njft) for polycythemia vera. Product is approved and commercially available in multiple markets including U.S., EU, Japan, and Canada. Q3 sales reached $127.8 million, up 44% year-over-year with 61% revenue growth and 89% gross margins over the trailing twelve months.
- Manufacturing Services: Expansion of manufacturing capacity through dual-site strategy (Taiwan and Puerto Rico) to support global demand for BESREMi and future pipeline products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | BESREMi 500 mcg/ml single syringe |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
PharmaEssentia product offering
Product offeringCore offering
PharmaEssentia is a Taiwan-based biopharmaceutical company that develops and commercializes BESREMi (ropeginterferon alfa-2b-njft), a proprietary mono-pegylated proline interferon therapy for adults with polycythemia vera and other myeloproliferative neoplasms. The company also manufactures biologic drug substance and drug product at GMP facilities in Taiwan and is building a second manufacturing site in Puerto Rico to support global supply.
Product overview
PharmaEssentia is a biopharmaceutical company with a focused portfolio anchored by BESREMi® (ropeginterferon alfa-2b-njft), an FDA-approved mono-pegylated proline interferon therapy for polycythemia vera (PV), now also available as a convenient prefilled pen device. The company is pursuing label expansions for BESREMi® in Essential Thrombocythemia (ET) and other MPNs, supported by a growing pipeline that includes PEGylated cytokines, checkpoint antibodies, TCR-T cell therapy, and bispecific immunocytokines leveraging a proprietary site-specific PEGylation technology platform. PharmaEssentia operates GMP biologics manufacturing facilities in Taiwan and is expanding into the U.S. (Puerto Rico) to support global demand.
Differentiator
Problem solved
Functional benefit
Brands
- BESREMi: FDA-approved product (ropeginterferon alfa-2b-njft) for treatment of adults with polycythemia vera
- BESREMi Pen
- Piece Together PV
- Piece Together ET
- PV in Focus
- PharmaEssentia SOURCE
- MPN Pod: Stories from the Marrow
- ChangePV
- PharmaEssentia Medical
Products and services
- BESREMi (ropeginterferon alfa-2b-njft) An FDA-approved, mono-pegylated proline interferon alfa-2b therapy indicated for the treatment of adults with polycythemia vera (PV). It delivers durable hematologic and molecular responses with a favorable safety profile and every-two-weeks dosing. Prescribed by hematologists and oncology specialists.
- BESREMi Pen (ropeginterferon alfa-2b-njft prefilled pen) FDA-approved prefilled pen device for self-administration of ropeginterferon alfa-2b-njft by adult patients with polycythemia vera. Designed to simplify administration and improve patient adherence compared to pre-filled syringe presentation.
- PharmaEssentia SOURCE Patient Support Program A patient services program providing personalized support to patients prescribed BESREMi to facilitate onboarding, access, adherence, and ongoing treatment continuation.
Quantifiable outcome
- 61% of patients achieved complete hematological response after 7.5 years of treatment
- +5 more outcomes
Companies that use PharmaEssentia
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
PharmaEssentia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PharmaEssentia partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor, core and secondary.
- Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)minorTaiwan government office organized 33-company delegation to BIO International Convention 2026. Supports cross-border investment, technology licensing, and joint co-development initiatives for Taiwan biotech companies.
- FORUS Therapeutics Inc.corePharmaEssentia acquired 100% of FORUS Therapeutics for US$36.5 million to integrate Canadian regulatory, medical affairs, marketing, and commercial channel resources. FORUS had previously submitted New Drug Submission to Health Canada for BESREMi in July 2025 and received approval in July 2026. The FORUS team brings more than 25 years of hematology and oncology commercialization experience with backgrounds at Celgene, Roche, Pfizer.
- TECH-TokyominorJointly created PharmaEssentia Innovation Award to support biotech startups in Taiwan and Japan. First prize of $100,000 with total prize pool of $200,000. Focus on blood disorders, cancer, rare diseases, autoimmune diseases, AI/ML drug discovery, and cell therapy platforms.
- Karyopharm TherapeuticsminorFORUS Therapeutics partnership opportunity for Karyopharm's XPOVIO product in Canadian market as part of PharmaEssentia's acquisition of FORUS.
- WuXi BiologicscoreEntered into exclusive global license agreement with WuXi Biologics for a myeloid immune checkpoint antibody candidate. Expands PharmaEssentia's pipeline into novel immune checkpoint targets.
- Pint-PharmasecondarySelected as commercial partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America regions to expand market access.
- AOP Health (AOP Orphan Pharmaceuticals GmbH)coreAOP Health acquired development and commercialization rights for BESREMi in European, CIS, and Middle Eastern markets from PharmaEssentia in 2009. Has made BESREMi available to approximately 12,600 patients in licensed territory. Frankfurt court upheld arbitral award in favor of AOP Health in April 2026.
Scale indicators12 records
Recent moves8 records
Expansion highlights8 records
PharmaEssentia competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: Broad oncology/hematology incumbent where Eric Vogel (now PharmaEssentia's US Head of Commercialization) previously held senior commercial leadership roles; comparable in targeting oncology specialists and rare cancer indications.
- Novartis: Major oncology/hematology incumbent with deep relationships with hematologists globally, including in MPNs and chronic myeloid disorders; represents the kind of broad competitor PharmaEssentia encounters in international markets.
- Roche: Global biopharma with extensive hematology/oncology portfolio and large specialty biologics infrastructure; operates in adjacent MPN/cancer therapeutics and competes for the same prescriber mindshare.
- Bristol-Myers Squibb: Acquired Fedratinib (Inrebic) for myelofibrosis via Celgene, directly competing in MPNs. BMS is a broad hematology/oncology incumbent with the commercial scale to compete against BESREMi across indications.
- Takeda Pharmaceutical: Global pharma with substantial hematology/oncology portfolio including rare blood disorder therapies (e.g., Adynovate for hemophilia); broad incumbent competing for the same specialty hematology prescriber audience.
Emerging players
- Disc Medicine: Clinical-stage biotech developing therapeutics for hematologic diseases including rare anemias and hematologic malignancies; comparable as an emerging player pursuing specialty hematology indications with differentiated biologics.
- Karyopharm Therapeutics: Specialty oncology biotech focused on hematologic malignancies (XPOVIO/selinexor); relevant emerging peer given PharmaEssentia's FORUS acquisition included a Karyopharm partnership for the Canadian market and overlapping focus on rare blood cancers.
Direct peers
- Incyte Corporation: Direct competitor in MPNs with Jakafi (ruxolitinib) as the standard-of-care for PV and myelofibrosis; both companies target hematologists/oncologists with specialty biologics for rare blood cancers. PharmaEssentia even hired ex-Incyte GVP Eric Vogel to lead US commercialization.
- AOP Orphan Pharmaceuticals (AOP Health): Exclusive commercial partner for BESREMi across Europe/CIS/Middle East since 2009; AOP Health is itself a rare disease specialty pharma focused on hematology/oncology including MPNs and directly comparable as a channel and as a competing MPN-focused company.
- Sobi (Swedish Orphan Biovitrum): European-headquartered rare disease specialty pharma with hematology/oncology focus, comparable to PharmaEssentia in business model (orphan/specialty biologics for rare blood disorders) and international footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
PharmaEssentia social profiles
Digital presencePharmaEssentia compliance and trust
Trust signalCompliance7 records
PharmaEssentia financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaEssentia leadership team
Management profileNumber of profiles
Profiles13 records
PharmaEssentia subsidiaries and ownership
Company hierarchySubsidiaries5 records
PharmaEssentia funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaEssentia M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaEssentia
What does PharmaEssentia do?
PharmaEssentia is a Taiwan-based biopharmaceutical company that develops and commercializes BESREMi (ropeginterferon alfa-2b-njft), a proprietary mono-pegylated proline interferon therapy for adults with polycythemia vera and other myeloproliferative neoplasms. The company also manufactures biologic drug substance and drug product at GMP facilities in Taiwan and is building a second manufacturing site in Puerto Rico to support global supply.
Is PharmaEssentia a public or private company?
PharmaEssentia is a public company. It is classified as public and is currently operating.
When was PharmaEssentia founded?
PharmaEssentia was founded in 2003. It employs 501 to 1,000 people.
Where is PharmaEssentia based?
PharmaEssentia is headquartered in Taipei, Taiwan, in the Asia region.
How does PharmaEssentia make money?
Two revenue lines are on record. Pharmaceutical Product Sales (BESREMi) is the primary driver. The others are manufacturing Services.
Who are PharmaEssentia's main competitors?
Broad incumbents on record are AstraZeneca, Novartis, Roche, Bristol-Myers Squibb and Takeda Pharmaceutical. Emerging players are Disc Medicine and Karyopharm Therapeutics. Direct peers are Incyte Corporation, AOP Orphan Pharmaceuticals (AOP Health) and Sobi (Swedish Orphan Biovitrum).
Does PharmaEssentia have an API?
No public API is recorded for PharmaEssentia.
What industry is PharmaEssentia in?
PharmaEssentia's product category is Hematology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 3254 and its SIC code is 2834.